Associated Banc Corp Sells 5,085 Shares of Johnson & Johnson (NYSE:JNJ)

Associated Banc Corp lessened its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 2.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 173,308 shares of the company’s stock after selling 5,085 shares during the period. Johnson & Johnson accounts for about 0.9% of Associated Banc Corp’s investment portfolio, making the stock its 29th biggest holding. Associated Banc Corp’s holdings in Johnson & Johnson were worth $27,164,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. Tower View Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Keener Financial Planning LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $40,000. WFA Asset Management Corp grew its stake in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after buying an additional 97 shares during the last quarter. Disciplined Equity Management Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $45,000. Finally, Altshuler Shaham Ltd raised its holdings in shares of Johnson & Johnson by 37.8% in the third quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock worth $49,000 after buying an additional 87 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $151.24 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a fifty day moving average price of $151.88 and a two-hundred day moving average price of $155.12. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The firm has a market capitalization of $363.99 billion, a PE ratio of 9.43, a P/E/G ratio of 2.49 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.68 earnings per share. As a group, analysts anticipate that Johnson & Johnson will post 10.64 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analyst Upgrades and Downgrades

Several brokerages have commented on JNJ. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Bank of America reduced their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Thursday, May 16th. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Finally, HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $175.86.

Read Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.